GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvation Bio Inc (NYSE:NUVB) » Definitions » Beginning Cash Position

Nuvation Bio (Nuvation Bio) Beginning Cash Position : $449.53 Mil (As of Sep. 2021)


View and export this data going back to 2020. Start your Free Trial

What is Nuvation Bio Beginning Cash Position?

Nuvation Bio's Beginning Cash Position for the quarter that ended in Sep. 2021 was $449.53 Mil.

Nuvation Bio's quarterly Beginning Cash Position increased from Mar. 2021 ($29.76 Mil) to Jun. 2021 ($638.90 Mil) but then declined from Jun. 2021 ($638.90 Mil) to Sep. 2021 ($449.53 Mil).


Nuvation Bio Beginning Cash Position Historical Data

The historical data trend for Nuvation Bio's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuvation Bio Beginning Cash Position Chart

Nuvation Bio Annual Data
Trend Dec20 Dec21
Beginning Cash Position
- -

Nuvation Bio Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Beginning Cash Position Get a 7-Day Free Trial - 29.76 638.90 449.53 -

Nuvation Bio Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.


Nuvation Bio Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Nuvation Bio's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.


Nuvation Bio (Nuvation Bio) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
1500 Broadway, Suite 1401, New York, NY, USA, 10036
Nuvation Bio Inc is a biopharmaceutical company. The company is engaged in developing therapeutic candidates for the unmet needs in oncology. The firm operates in pharmaceutical, biotechnology and other related markets that develop small molecules and drug conjugates as treatments for cancer patients.